Merck & Co and Sun Pharmaceutical are winding down their 2011 joint venture focused on developing branded generics for emerging markets outside of India.
Sun Pharma said the move follows a change of strategic priorities for both partners, which have decided not to invest further in the JV.
Dilip Shanghvi, Sun’s managing director, reportedly told analysts that the firm’s investment in the venture is not significant and has been factored into the company’s financials over time, according to The Hindu Business Line.
Other agreements between the firms – the co-marketing deal for Merck’s diabetes drug Januvia (sitagliptin) and licensing deal for Merck’s investigational psoriasis therapy tildrakizumab – remain unaffected by the decision, the Indian generics giant stressed.
By Selina McKee
Source: Pharma Times
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.
